Studies have demonstrated that inhibition of HuR can enhance therapeutic efficacy of certain therapeutic strategies by inhibiting stressors (e.g., hypoxia, glucose deprivation, chemotherapies) that induce HuR cytoplasmic localization in pancreatic cancer cells [18, 59–61]. This evidence concerns the gene ELAVL1 and pancreatic neoplasm.